Quantitative brain MRI is usually requested once there is already a reason to suspect something. By that point, the analysis can describe where a patient’s brain is today. It cannot describe the path that led there. In neurodegenerative disease, the direction of travel is often more informative than the position.
A percentile compares a patient to a population, not to that same patient over time
Normative percentiles answer a real question: how does this brain compare to others of similar age and sex?
They cannot answer a second question: how does this brain compare to its own prior state?
A hippocampal volume in the lower range of normal may represent longstanding normal variation for that individual. It may also represent meaningful decline from a considerably higher starting point. Those two situations can appear similar on a single examination, and they may carry very different clinical implications.
Distinguishing between them requires a prior quantitative reference point. Without one, the interpreting physician is left with a position and no trajectory.
Rate of change is where the clinical signal concentrates
Age-related volume loss follows broadly expected patterns. Loss that outpaces those patterns is a different observation, and it is one that can only be made across time.
A second quantified examination converts a static measurement into a rate. That rate can support a clinician in distinguishing expected aging from something progressing faster, in documenting stability when a patient is anxious about symptoms that turn out to be nonprogressive, and in tracking response after an intervention.
None of this establishes a diagnosis. It provides objective, reproducible measurement that a physician can weigh alongside conventional images, clinical examination, and history.
That rate is only available, however, when an earlier point exists against which to measure.
The information also has value at the first point of interpretation
The longitudinal case is the strongest one, but it is not the only one.
Even on a first examination, quantitative analysis provides objective measurement where visual assessment would otherwise carry the burden alone. Regional volumes are reported with normative context. Asymmetry is measured rather than estimated. Findings are documented in a form that is reproducible between readers and available to the next clinician who opens the record.
For subtle changes in particular, quantitative measurement can surface information that conventional visual review may not readily resolve.
The value extends well beyond cognitive indications
Framing volumetric analysis primarily as a dementia tool understates where objective measurement contributes.
In multiple sclerosis, lesion burden and volume trajectory provide additional context alongside conventional interpretation of disease activity.
In epilepsy, hippocampal and regional asymmetry can be quantified rather than judged visually.
For patients with a history of head injury, particularly those in higher-risk occupations or activities, an earlier quantitative reference point may inform how a subsequent examination is understood.
In many patients, the most useful result will be a well-documented, unremarkable baseline. That is not a wasted analysis. It is a reference point that now exists in the record.
Why a quantitative baseline matters before symptoms do
A substantial share of brain MRI volume is ordered for nonspecific indications. Headache. Dizziness. Unsteadiness. Trauma follow-up. Neurodegenerative disease is not the question being asked, and nothing about those encounters suggests that quantitative analysis is necessary.
Some proportion of those patients will present years later with cognitive symptoms. Which patients those will be is not knowable at the time of the first examination.
That is the practical difficulty with selective processing. It requires identifying who will benefit from a baseline before any indication of who they are exists.
Worth noting: a prior examination is not necessarily lost. Provided a suitable 3D T1 volumetric sequence was acquired, an older study can be submitted and processed retrospectively, which means an existing archive may hold usable baselines already.
The binding constraint is acquisition, not processing. If the volumetric sequence was never obtained, no amount of later effort recovers it. If it was obtained, the baseline is recoverable.
Routine processing still matters, because information that is already in the record at the moment a clinician needs it behaves very differently from information that depends on someone locating, retrieving, and submitting a study from several years earlier.
How an unlimited subscription changes the calculation
CorTechs Labs offers NeuroQuant modules under an unlimited subscription rather than per-study pricing. An organization licenses the technology, and eligible examinations are processed without a separate charge attaching to each individual analysis.
Per-study pricing rations by cost rather than by clinical judgment
Under a per-analysis model, every case presents a small financial question before it presents a clinical one. Is this particular patient worth an additional charge?
With the unlimited subscription model that Cortechs offers, patient stratification for NeuroQuant eligibility becomes unnecessary. This helps simplify workflow and improve cognitive burden on MRI staff and referring physicians without incurring added expense.
The existing archive becomes accessible
Because retrospective processing carries no incremental charge, prior examinations that included a suitable 3D T1 sequence can be submitted and quantified. An organization may already hold usable baselines across years of stored studies.
Under per-study pricing, a project of that kind would require case-by-case financial justification, which is generally enough to prevent it. Under an unlimited subscription, it becomes a workflow question rather than a budget question.
Budgeting no longer depends on volume forecasting
Per-analysis pricing requires an organization to estimate how many studies it will process, revisit that estimate as referral patterns shift, and often manage internal chargeback between departments.
A fixed subscription removes those exercises. Cost is predictable regardless of whether utilization grows, which means growth in appropriate use never becomes a budget problem that someone must defend.
The question the model makes possible
An unlimited subscription reframes what an organization is deciding.
The question stops being which patients should receive quantitative analysis. It becomes which eligible patients would benefit from having quantitative information available to their physician.
Those two questions produce meaningfully different workflows, and only the second is a purely clinical question.
The question a baseline makes available
The value of a quantitative baseline is unusual in that the clinician who orders it rarely realizes that value.
It is realized later, on a subsequent examination, possibly by a different physician, who is finally able to ask a question that would otherwise have no answer.
Has this changed?
That question becomes available only when there is a quantitative analysis from a prior study.
